Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Bok S, Greenblatt MB. Shaping the sinuses: a novel Krt14+Ctsk+ cell lineage driving regenerative bone formation. Cell Res. 2022;32(9):791-792.

Lin M, Ku AT, Dong J, Yue F, Jiang W, Ibrahim AA, et al. STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential. Oncogene. 2022;41(48):5214-5222.

Butler-Laporte G, Gonzalez-Kozlova E, Su C-, Zhou S, Nakanishi T, Brunet-Ratnasingham E, et al. The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals. Clin Proteomics. 2022;19(1):34.

Brady NJ, Patel PS, Moayedi S, Sward D. A novel source of carbon monoxide for suicide attempt. Undersea Hyperb Med. 2022;49(3):329-331.

Karamchandani DM, Gonzalez RS, Westerhoff M, Westbrook LM, Panarelli NC, Al-Nuaimi M, et al. Measuring depth of invasion of submucosa - invasive adenocarcinoma in oesophageal endoscopic specimens: how good are we? Histopathology. 2022;80(2):420-429.

Lucas F, Mata DA, Greenblatt MB, Means J, Jarolim P. A Potassium-Based Quality-of-Service Metric Reduces Phlebotomy Errors, Resulting in Improved Patient Safety and Decreased Cost. Am J Clin Pathol. 2022;157(5):789-798.

Rosenthal J, Carelli R, Omar M, Brundage D, Halbert E, Nyman J, et al. Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology. Mol Cancer Res. 2022;20(2):202-206.

Leeman-Neill RJ, Soderquist CR, Montanari F, Raciti P, Park D, Radeski D, et al. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. Haematologica. 2022;107(1):201-210.

Jang J-, Hwang I, Pan H, Yao J, Alinari L, Imada E, et al. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. J Clin Invest. 2022;132(24).

Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):219-229.